A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs
Pfizer gets obesity drug approval in China shortly after buying local rights
Pfizer gets obesity drug approval in China shortly after buying local rights
Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations
Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations
After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push
Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push
Nektar posts one-year eczema success; Pfizer ends malnutrition trial
Nektar posts one-year eczema success; Pfizer ends malnutrition trial
The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more
The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more
Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study
Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study
Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan
Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan
Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges
Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges
Pfizer dips on new data for obesity drug acquired in $10B deal
Pfizer dips on new data for obesity drug acquired in $10B deal
Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b
Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b
Pfizer takes $4.4B charge related to cancer drug in fourth-quarter earnings
Pfizer takes $4.4B charge related to cancer drug in fourth-quarter earnings
Pfizer’s Metsera-originated monthly GLP-1 cuts weight by 10.5% at six months
Pfizer’s Metsera-originated monthly GLP-1 cuts weight by 10.5% at six months
Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs
Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs
Pfizer to depart GSK's ViiV as Shionogi doubles its stake
Pfizer to depart GSK's ViiV as Shionogi doubles its stake
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page